Evidence map›Paper›PMID 40223180›Full record

ArticleTransfusion2025

HIV incidence in US first-time blood donors during 12 and 3 month deferral policy periods between 2015 and 2023 before implementation of individual donor assessment.

Eduard Grebe, Clara Di Germanio, Edward P Notari, Mars Stone, Jahnavi Reddy Bhaskar, Venkata Dayana, Marion C Lanteri, Jed Gorlin, Rita Reik, Susan L Stramer and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Eduard GrebeVitalant Research Institute, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-7046-7245
Clara Di GermanioVitalant Research Institute, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-6047-211X
Edward P NotariAmerican Red Cross, Rockville, Maryland, USA.
Mars StoneVitalant Research Institute, San Francisco, California, USA.
Jahnavi Reddy BhaskarVitalant Research Institute, San Francisco, California, USA.
Venkata DayanaVitalant Research Institute, San Francisco, California, USA.
Marion C LanteriUniversity of California San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-4213-5013
Jed GorlinNew York Blood Center Enterprises, New York, New York, USA.
Rita ReikOneBlood, St Petersburg, Florida, USA.
Susan L StramerInfectious Disease Consultant, North Potomac, Maryland, USA.
Michael P BuschVitalant Research Institute, San Francisco, California, USA.
Benyam HailuNational Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Artur A BelovFood and Drug Administration, Silver Spring, Maryland, USA.ORCID https://orcid.org/0000-0001-6848-1224
Hong YangFood and Drug Administration, Silver Spring, Maryland, USA.
Barbee WhitakerFood and Drug Administration, Silver Spring, Maryland, USA.ORCID https://orcid.org/0000-0002-6311-6268
Brian CusterVitalant Research Institute, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-6251-366X
US Transfusion‐Transmissible Infections Monitoring System (TTIMS)

Funding

FDA HHS 75F40120C00101FDA HHS 75F40121C00196National Heart, Lung, and Blood Institute (NHLBI)National Institutes of Health (NIH)National Institutes of Health (NIH) 10.13039/100000002U.S. Department of Health and Human Services
6 · The paper itself

Abstract

backgroundFollowing FDA guidance, US blood collectors changed donor deferral for men who have sex with men (MSM) from indefinite to a 12 month deferral in 2016 (12 m), and for MSM and several other exposure risks to 3 month deferrals in 2020 (3 m). We evaluated first-time donor (FTD) HIV incidence and demographics during these periods. STUDY DESIGN AND

methodsWe estimated cross-sectional HIV incidence and incidence rate differences in FTD based on routine donation nucleic acid testing (NAT) and serology with additional limiting antigen (LAg)-Avidity immunoassay and viral load testing. We estimated incidence in the two policy periods (12 and 3 m), incidence trends in two-year intervals between 2015 and 2023, and used multivariable Poisson regression to assess demographic correlates of incident infection.

resultsHIV incidence in FTD during the 12 m deferral period was 2.82 infections/10 DISCUSSION: HIV incidence in FTD did not increase between 2015 and 2023. An overall decline in HIV incidence in the 3 m deferral period compared with the 12 m deferral period was evident. These results provide no indication of an increased residual risk of transfusion-transmitted HIV from FTD in the United States with the reduced deferral periods.

Indexed as

Blood DonorsDonor SelectionHIV InfectionsAdultCross-Sectional StudiesFemaleHomosexuality, MaleHumansIncidenceMaleMiddle AgedUnited StatesYoung AdultHIVtransfusion‐transmitted disease

Identifiers

PMID40223180
PMCPMC12088899

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.